Halozyme prices upsized $1.3B 1.50% converts due 2033
Halozyme priced $1.3B of 1.50% convertible senior notes due 2033, upsized from $1.05B. The initial conversion price was $139.84, with capped calls to $208.39. Net proceeds were about $1.275B.
Halozyme priced $1.3B of 1.50% convertible senior notes due 2033, upsized from $1.05B, with a $139.84 initial conversion price and capped calls to $208.39. Net proceeds are expected to be about $1.275B, with part of the proceeds used to repurchase about $151.7M of 2027 notes and $220.0M of 2028 notes.